Literature DB >> 8324147

Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.

D W Hecht1, J R Osmolski, J P O'Keefe.   

Abstract

The antimicrobial susceptibility of isolates of the Bacteroides fragilis group from six hospitals in the Chicago area varied from one institution to another; this variation was similar to the geographic variation documented in a national survey. A total of 365 B. fragilis group isolates were tested against 10 antibiotics. Imipenem, piperacillin/tazobactam, ampicillin/sulbactam, ticarcillin/clavulanate, and cefoperazone/sulbactam had excellent activity against all members of the B. fragilis group, with little interhospital variation. Cefoxitin and ceftizoxime had very good activity, also with little variation among hospitals. Clindamycin, cefotetan, and cefmetazole had the lowest level of activity, with unusually high-level resistance confined to three of the six hospitals. These data indicate that variation in the antimicrobial susceptibility of these bacteria is likely based in the hospital rather than in the geographic region and that the in vitro activity of certain antibiotics against B. fragilis group isolates from individual hospitals cannot be predicted from the data obtained in larger-scale surveys.

Entities:  

Mesh:

Year:  1993        PMID: 8324147     DOI: 10.1093/clinids/16.supplement_4.s357

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

Review 2.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 3.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

4.  Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

Authors:  David W Hecht; J R Osmolski
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Clinical and therapeutic features of nonpostoperative nosocomial intra-abdominal infections.

Authors:  Philippe Montravers; Annie Chalfine; Remy Gauzit; Alain Lepape; Jean Pierre Marmuse; Corinne Vouillot; Claude Martin
Journal:  Ann Surg       Date:  2004-03       Impact factor: 12.969

6.  Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State.

Authors:  Jeffrey M Schapiro; Rachna Gupta; Eric Stefansson; Ferric C Fang; Ajit P Limaye
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

7.  Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Authors:  Christine J Hastey; Halsey Boyd; Audrey N Schuetz; Karen Anderson; Diane M Citron; Jody Dzink-Fox; Meredith Hackel; David W Hecht; Nilda V Jacobus; Stephen G Jenkins; Maria Karlsson; Cynthia C Knapp; Laura M Koeth; Hannah Wexler; Darcie E Roe-Carpenter
Journal:  Anaerobe       Date:  2016-07-15       Impact factor: 3.331

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.